The eye area behind dark tortoise frames: the eye cream ranking's own hero, standing at the head of a Take argued from that Card, because every claim on that shelf is finally a claim about this surface and what is put on it. The frame shows a face, not a bottle: the photo bank holds no eye cream product photography, no bottle or dropper frames and no bathroom-shelf frames, a gap the ranking names on its own page and the honesty section below admits in full.

Checked and updated October 2026

The thesis: the copy is not the list

This column keeps finding the same shape of gap on the bathroom shelf, in different units: a claim whose substance is printed incompletely or not at all. The eye shelf is the eighth case, and it is the first in which the substance is printed completely and the claim still fails. On the shelves before it, something was always missing: a dose, a duration, an itemised scent, a panel. Here nothing is missing. Every maker in the field publishes his full ingredient list, the shelf's documents run from 20 items to about a hundred, and a reader with patience can reconstruct every formula on the page. The gap on this shelf is not between the claim and an absent document. It is between two documents the same maker prints, the copy that sells the bottle and the list that inventories it, and on one bottle the two describe different formulas. The copy is not the list, and only one of them is the inventory the law requires.

Start with what the product is, because the Card is exact about it and the exactness is the argument. An eye product is one job in three forms: the cream, an emulsion with an occlusive system, the default; the gel-cream, silicone and humectant led, worn light; the serum, a water system with no occlusive layer at all, which delivers its active and leaves, and is honest about the leaving. The Card grades each form on the fullness of its list and the truth of its claims against that list, and its form paragraph prints the rule this Take is built on, in words: what no form may do on this page is sell an ingredient its list does not contain. It is the strictest sentence the Card prints, stricter than anything it says about dose or fragrance, because it is the one rule that does not depend on position, panel or price. An ingredient is on the list or it is not. The shelf, counted entire, breaks that rule once, in its longest document, in the open.

The bottle is the Brickell Restoring Eye Cream, ranked seventh at 65, and its record deserves reading the way the Card prints it, because the finding is documentary from end to end. The list is the longest the grooming run has graded, about a hundred items, read entire on the maker's own product page: purified water, aloe second, sunflower oil third, cassia seed polysaccharide, the plant hyaluronic acid of the copy, witch hazel fifth, glycolic acid sixth, MSM seventh, and on through sodium ascorbyl phosphate, Matrixyl 3000 named as a trade name in the list itself, palmitoyl tripeptide-5, cucumber hydrosol, and a botanical tail that runs to helichrysum, geranium, lavender and lemongrass essential oils. It is, as a document, a stocked pantry: two acids high, a vitamin C salt, peptides named, nothing withheld. Against that list, the same page's copy credits caffeine with increasing blood flow to the eye area. The same maker's FAQ names caffeine among the formula's workers. The same maker's key-ingredient panel lists caffeine. And the published list contains no caffeine entry at all. Three venues claim the ingredient, copy, FAQ and ingredient panel, and the fourth document on the page, the inventory itself, does not carry it. The desk did not catch this by testing or by suspicion. It caught it the way the Card says it did: the list is published in full, all hundred items, for any reader to check, which is how the desk caught it. The maker's transparency is what convicts his copy, and the score, an honesty row of 19 inside a 65, prices exactly that combination.

Set the finding against the shelf, because caffeine is not an obscure material on it and its genuine appearances are all documented. Caffeine stands on three of the eight lists: second of 26 in the serum, where it is dosed at 5 percent and the dose is printed in the product's name; sixth of 34 in the Kiehl's gel-cream; about fifteenth on the skip's list. Three bottles employ it and print it, in the order their formulas carry it, and a fourth claims it in three places and prints it nowhere. The claim is not even implausible, which is what makes it instructive: caffeine is the shelf's one fashionable active, the one a formulator would reach for and the one a copywriter would assume. But the desk grades documents, and on the documents the Brickell's caffeine exists only in prose. A claim about an ingredient the document does not carry is the honesty failure this run exists to catch, and it is a cleaner catch than any the run has made, because no rendering, no panel and no supplier stands between the claim and the list. They are on the same page.

The dose column, counted across the shelf, shows the same documentary split at a smaller scale. A headline active with a printed percentage stands on one of the eight bottles: The Ordinary's caffeine, 5 percent, in the name, its position, second of 26, agreeing with its percentage, which on this shelf counts as corroboration. Everything else travels on position alone. Niacinamide stands second of 41 in the winner, fourth of 34 in the Kiehl's and eighth of 20 in the La Roche-Posay, three strong positions and not one percentage between them. The vitamin C forms, ascorbyl glucoside at twenty-first of 34, ascorbyl palmitate at twenty-seventh of 48, sodium ascorbyl phosphate buried in a list of about a hundred, carry no number anywhere. The field's one retinoid is retinyl palmitate, the gentle ester, at twenty-sixth of 48, undosed. Position is real evidence, and this column has always read it as evidence; but position ranks inside one list and cannot be spent across two, and a percentage is the only figure that can. The shelf prints exactly one, and it prints it in a name, on the cheapest bottle in the field, at $9.20 for a full ounce. The dose, where it exists at all, is a drugstore habit.

And where percentages do circulate on this shelf, they live one document away from the bottles. The Jack Black's copy leads with a peptide complex clinically proven to reduce the appearance of deep surface wrinkles by up to 28 percent, footnoted, in the maker's own words, as based on supplier data: the supplier's panel for the ingredient, not a test of this bottle. The Brickell's retail copy carries a 45 percent the same way. Two precise figures, both real, both printed, and neither a dose of anything a reader can buy: they measure what the ingredient did in its maker's laboratory, in some other formula, at some other strength. The peptide column completes the pattern. Peptides stand on four of the eight lists, the La Roche-Posay's neurosensine twentieth and last of 20, the Kiehl's pair at thirty-second and thirty-fourth of 34, the Jack Black's at seventeenth of 48, the Brickell's deep in its hundred, and four of four stand in the bottom half, dosed on none. The class this shelf is marketed on is documented as a garnish and evidenced as a percentage that belongs to somebody else. The winner and the serum, the two bottles whose claims their lists can cash entire, a barrier system in the middle of one list and a dose in the other's name, finish first and second. The two bottles sold hardest on peptides finish sixth and seventh. The graded order of the shelf is the argument, printed before this Take argues it.

Nothing on this page is scored. Every score quoted here, every row, every price and every count is the eye cream ranking's, Verdict Card No. 90, reproduced exactly as that Card published it: CeraVe Eye Repair Cream at 87, The Ordinary Caffeine Solution 5% + EGCG at 84, La Roche-Posay Toleriane Dermallergo Eye Cream at 82, Kiehl's Eye Fuel at 76, Neutrogena Hydro Boost Eye Gel-Cream at 74, Jack Black Protein Booster Eye Rescue at 73, Brickell Restoring Eye Cream at 65, and Lumin Dark Circle Defense Balm sent home at 45. The only arithmetic of this page's own is counting what the Card's record prints: how many lists are published whole, how many actives are dosed, where the peptides stand, which claims a list carries and which it refuses, and what the shelf's two circulating percentages actually measure. Two precisions in this issue's own brief, the claim's third venue and the documentary limit on the word refuted, are confessed in the honesty section, in words, because a column about grading claims against lists should print its own corrections where its readers can find them.

The record, counted

Start with the list column, because its completeness is what makes the rest of the census possible, and because on this shelf the completeness has a texture worth printing. Full ingredient lists published: eight of eight. Provenance varies, and the Card prints the variation rather than tidying it away: the winner's list is the fuller of two circulating renderings, read on its Ulta panel, the second rendering printing sodium hyaluronate and aloe leaf extract where the graded one prints the hydrolysed acid and the leaf juice powder; the La Roche-Posay's list was read on its European retail rendering, the maker's American page printing its key ingredients, its price and its testing record, which agree with the rendering's positions; the Neutrogena's was read on a national retailer's ingredient panel, the maker's own page not rendering its panel through the desk's routes; the Jack Black's stands on the 48-item published ingredient record; the Brickell's was read entire on the maker's own product page, which is the provenance that matters most in this census, because the shelf's headline disagreement is between two documents on that one page. Three records, in the Card's count, rest on retail or ingredient records where the maker's own panel resisted capture, and the limit is printed on each. Against that base, the shelf's four columns can be counted separately: the dose, the peptides, the copy, and the scent.

The dose column first, since it is the shortest. A headline active with a printed percentage: one of eight, The Ordinary's caffeine at 5 percent, printed in the product's name and standing second on its 26-item list. No other active on any list carries a figure: not the niacinamide that stands second, fourth and eighth on three lists; not the three vitamin C forms, a glucoside, a palmitate and a phosphate salt, at twenty-first of 34, twenty-seventh of 48 and deep in a hundred; not the field's one retinoid, retinyl palmitate at twenty-sixth of 48, an ester where the copy's readers will picture retinol. Caffeine itself, the shelf's test material, stands on three lists, second of 26, sixth of 34 and about fifteenth on the skip's, a spread the Card prints so the Brickell's absence can be measured against it: the ingredient is present at the top of one list, the middle of another and the tail of a third, and the claim examined in the thesis stands on a fourth page with no entry at any position. A measured dose in millilitres, meanwhile, is printed by none of the eight: the packaging is the closest thing to dose control the shelf sells, one jar, one airtight pump, one dropper and tubes for the rest, and the jar, which doses nothing and asks for a finger in the pot twice a day, belongs to the bottle with the claimed ingredient. The dose column and the copy column are the same column read twice: the shelf's least controlled document belongs to its least controlled claim.

The peptide column is the census's second count, and its numbers are the shelf's marketing read backwards. Peptides on four of eight lists. Their positions: the La Roche-Posay's neurosensine, acetyl dipeptide-1 cetyl ester, twentieth and last of 20, the maker's named key ingredient standing behind every emulsifier and preservative on its own list; the Kiehl's pair, palmitoyl oligopeptide thirty-second and palmitoyl tetrapeptide-7 thirty-fourth and last of 34, the two ingredients the copy leads with queueing at the tail; the Jack Black's palmitoyl oligopeptide at seventeenth of 48, the highest peptide position in the field and still the bottom half's far edge; and the Brickell's, Matrixyl 3000 named as a trade name in the list itself, palmitoyl tripeptide-5 beside it, deep in a list of about a hundred items. Bottom half: four of four. Dosed: none of four. And the evidence column that rides on them: consumer panels printed on three of the eight records, of 19 and 23 people for the serum's perception testing, self-assessed, and 33 for the skip's consumer study, while the La Roche-Posay prints its four-week percentages, 98, 94 and 92, with no panel size at all. The percentages with denominators belong to perception; the percentages without, 28 and 45, belong to suppliers. Nowhere on the shelf does a percentage describe the dose of an active in the bottle it is printed beside. That sentence, counted four ways, is the record this Take argues from, and the shelf's two peptide-led bottles, ranked sixth and seventh at $80 the ounce each, are its arithmetic made visible.

The copy column closes the count, and it is a column of specific sentences, graded as the Card grades them. First, the headline: caffeine credited with increasing blood flow to the eye area in the Brickell's copy, named among the formula's workers in its FAQ, listed in its key-ingredient panel, and absent from its published list, one active claimed in three documentary venues and carried in none. Second, the same bottle's scent sentence: sold as unscented, its list names several essential oils, helichrysum, geranium, lavender, lemongrass, which are ingredients, and are also, on any honest reading, a scent; a smaller disagreement of the same species, between a label word and a list, printed on the same card. Third, the skip's dressing: an espresso shot for the eyes, and clinical results whose substance is a consumer study of 33 participants over three weeks, whose printed headline is that all of them would recommend the balm to a friend, a satisfaction number wearing a lab coat. Fourth, the precedents the run has already counted, because the pattern is older than this shelf: on the aftershave Card, a ranked balm's retail copy claimed aloe and allantoin, neither on any captured version of its list, charged in its honesty row; on the beard shelf, disease benefits rode a maker's boilerplate. The eye shelf's version is the pattern at its most checkable, claimed not in a retail listing's boilerplate but in the maker's own FAQ and ingredient panel, the two venues a reader consults precisely because they are supposed to be documents rather than persuasion. The claims column and the list column, laid side by side, give the shelf's arithmetic: the lists are complete on eight of eight, the claims are cashed entire on the top two bottles, and the failures concentrate exactly where the copy writes cheques in a document's name.

The fragrance column is the census's shortest count and its control case. A Fragrance or Parfum entry: one of eight lists, the skip's, at the tail of about 45 items with its allergens, citronellol, limonene and geraniol, itemised behind it. Seven makers keep fragrance out of the eye area entirely, at every price on the shelf, the $9.20 serum and the $80 ounces alike. The count matters to this issue because it proves the shelf's documentation is a choice exercised well wherever makers choose it: a category whose standard advice is to keep scent away from the thinnest skin on the face has made fragrance-free its default, documented, at no premium. A shelf that can standardise the hard discipline cannot plead genre for the easy one. Printing what is in the bottle is this field's proven habit. The one bottle that claims an ingredient its list omits is not following its shelf. It is leaving it, in the opposite direction from the skip, and the scores say so in the same currency, 65 for the claim its list refuses, 45 for the fragrance its category refuses.

What the copy costs

The first cost is comparison, and on this shelf it falls on the shelf's fashionable active. A buyer shopping caffeine eye creams, a reasonable errand, meets four documents: a dose printed in a name at 5 percent, an entry standing sixth of 34, an entry at about fifteenth on a 45-item list, and a claim standing in a copy block, an FAQ and an ingredient panel over a list with no entry at all. Three of the four documents can be compared, by position and by dose, weakly in the way of this shelf but honestly. The fourth cannot be compared at all, because it offers nothing to compare: no position, no percentage, only an assertion wearing the same vocabulary as the other three. Until the lists are read whole, the assertion is indistinguishable from the serum's fact, which is the injury in its exact form: the copy borrows the credibility that the list's genre has earned, the regulated, checkable, hundred-item document, and spends it on a sentence the document contradicts. A shelf where assertions and entries trade at the same value is a shelf where entries are worth less, and the makers who print them, seven of eight here, are the ones who pay.

The second cost is at the till, and its shape by now is the run's familiar one. The ounces run from the serum's $9.20 through the winner's $39.98 and the pump bottle's $44.76 to the two dearest ounces at $80.00, and the two dearest are ranked sixth and seventh: the Jack Black, whose peptide claim is footnoted to a supplier, and the Brickell, whose caffeine claim is footnoted to nothing. The only dosed active in the field is in its cheapest bottle; six of the eight bottles are half an ounce or under, so the fraction itself, the unit the shelf is sold in, is where the margin lives, and the documents do not scale with the price in any row. Nothing in the spread is explained by documentation. The buyer is charged for the bottle, and the standard of its paperwork, whether its claims are entries, positions, supplier figures or assertions, is thrown in at whatever level the maker felt like meeting, which at the top of the price range is the shelf's lowest.

The third cost is paid by the reader who screens, and the eye area is where screening matters most. A claim that stands in copy but not in the list cannot be screened in either direction. The reader who wants caffeine, for the morning brief the shelf sells it on, cannot distinguish the bottle that employs it from the bottle that describes it without reading a hundred items to the end, which is to say the claim has taxed exactly the diligence it should reward. The reader avoiding an ingredient is worse served: he reads lists because lists are the screening document, and a maker whose prose and inventory disagree has made the prose a hazard, since the next disagreement may run the other way, an unlisted allergen described as absent. The shelf prints the stakes in its fragrance count: the one category where the skin is thinnest has standardised fragrance-free lists precisely so the screening reader can work. One maker's page teaches him that even on this shelf, the screening is only as good as the maker's proofreading, and the lesson generalises past the bottle that taught it, which is why a single refuted claim costs more than a low score.

The fourth cost is escalation, and the shelf prints the whole staircase in eight bottles. The first step is position: an active present but undosed, standing where garnishes stand, sold in the copy's headline, which is the Kiehl's and the La Roche-Posay's step, charged lightly because the ingredient is at least employed. The second step is the borrowed figure: a percentage that is real, published and somebody else's, the supplier's 28 and 45 riding in retail copy beside bottles that print no dose of their own. The third step is the assertion: an ingredient claimed in the FAQ and the ingredient panel, the two places a reader goes to escape copy, over a list that does not contain it. Each step borrows a stronger document's authority for a weaker sentence, and the staircase is climbed in the direction the money points, because each step is cheaper than the documentation it replaces. The shelf also prints its antidote, twice over, at the first and second ranks: a winner whose claims are positions its list can cash, and a serum whose maker prints his dose in the name and his panels at their size, 19 and 23 people, self-assessed, a maker understating his evidence in a field of overstatements. A shelf where the two most documented bottles finish first and second is a shelf where the record is still winning. The count that matters for the next shelf is whether the third step stays one bottle's step, or becomes a dialect.

The other side, stated fairly

The case against this Take is a serious one, and it runs in three parts. First: copy describes effect and experience, not contents. Marketing language answers what a product is for; a FAQ that names caffeine among the formula's workers is speaking in the grammar of benefits to a reader asking what the cream does, and nobody reads a benefits answer as an inventory. The inventory exists, is printed on the same page in full, and is the proper place to check contents; a column that grades the benefits grammar against the inventory's standard has mistaken one genre for another, like faulting a menu for not being a recipe. Second: lists are legal documents with their own ordering rules, and a website's rendering of one is a rendering. Below one percent, items may stand in any order; materials arrive inside premixes and under trade names; formulas are revised and pages lag; this very shelf circulates the winner's list in two versions with two names swapped, so the desk knows a published list can trail the jar in the warehouse. Absence of a word from one rendering is a documentary gap, not proof about the contents of the tube a reader buys, and the caffeine may stand in the current jar under a list the website has not caught up with. Third: a claim can be true of the formula family and absent from one bottle. Ranges share panels, FAQs and copy blocks across siblings; this shelf itself prints a caffeine sibling, Neutrogena's Hydro Boost+, beside its caffeine-free original, so a maker's FAQ written once for a family can carry a sibling's worker into the wrong bottle's page as an editorial slip, an error of filing rather than of faith, and a desk that convicts a filing error of bad faith has graded a man's intentions, which no document can show.

Each part is true about something, and the record answers each on its own ground. To the genre defence: conceded for metaphor, and refused for the venues in question. This desk has never graded a metaphor; the espresso shot on the skip's copy is charged as dressing, at the weight dressing deserves, and the winner's own poetry is read the same way. But caffeine is not an effect word. It is a material, with a regulated name of its own, and the claim stands in three places, only one of which is copy in the genre's sense. A key-ingredient panel is an inventory by genre: it exists to enumerate what is in the bottle, and a reader who finds caffeine enumerated there has been handed an inventory entry, not a benefit. An FAQ answer that names the formula's workers, on the page where the formula is printed entire, is a documentary act wearing a conversational tone. The genre defence covers the sentence in the advertising block. It does not reach the panel, and it does not reach the FAQ, and the claim stands in all three.

To the rendering: the limit is conceded, and conceded in the Card's own words before it is conceded here, because the Card prints the invitation itself: if the jar in a reader's hand prints a list with caffeine on it, the maker is invited to publish that list where a reader can find it, and the card will be re-read in November. This Take claims the documentary fact only, that the claim and the published list cannot both be read as true of the same bottle. But the concession cuts less than the counter needs, for three reasons the record supplies. The list was read entire on the maker's own product page, the freshest document a maker publishes, beside the very FAQ and panel that claim the ingredient; a lag that explains the list would have to spare the copy standing next to it. The claim is not one lagging line but three venues in agreement with each other and in disagreement with the inventory, which is the shape of a formula the copy was written for and the list was not, or the reverse, and either way the page as published describes two formulas. And the buyer, finally, can only grade what is published: a desk that excused every disagreement as a possible lag could grade nothing, and the shelf's other seven makers, whose pages agree with themselves, show the standard is meetable in the present tense.

To the family: the desk's standing practice is the answer, and the shelf prints it. Documents belong to bottles. The Neutrogena sibling is printed ungraded, as a note on its brother's card, precisely because its stronger document, caffeine fifth on its own list, is a different bottle's record and earns that bottle nothing here. A reader at the Brickell's page is buying this jar, reading this FAQ, over this list; a family document that assigns a sibling's active to this bottle has made this bottle's claim, in the place where this bottle is sold, and it is graded where it stands. The filing-error framing also meets the shelf's own control: the error, if error it is, survived in three venues, in a benefits sentence, a workers list and an ingredient panel, each of which a proofreader reads against the formula as a matter of routine, while the formula itself is printed in full one scroll away. Sincerity is conceded as biography, as it was on the beard shelf; it explains the sentence, and it does not make the sentence carryable by the list beneath it. The grade is of the page, which is all a reader is ever offered.

The picks, as published on the Card

The discipline for using any of them is the Card's, unchanged: eye cream goes on the orbital bone, not the lid, less than instinct says, a pea-sized amount split between both eyes, tapped along the bone with the ring finger, morning and night, and the pump and the dropper dose the small amount for you where the jar makes you guess. The standing offer of this column applies to the shelf in its own terms: the first maker on this shelf to print on his list what his copy already claims, or to dose the peptide his bottle is sold on beside its name on the bottle itself, will be named here, at the top of a re-argued column, the same day its record can be read. The documents exist in every maker's files. On one page they are already printed, a scroll apart, disagreeing.

What this page does not claim

On the evidence. This page scores nothing and tests nothing. Every score, row, price and position is Verdict Card No. 90's, reproduced exactly as that Card published it, and the Card's own evidence discipline stands behind them: the desk grades published ingredient lists in the maker's order, makers' claims graded as claims, reported wear labelled as reported wherever it appears, and prices per ounce with the arithmetic printed, and asserts nothing about what any cream does to any eye. The counts this Take adds, full lists on eight of eight, a printed percentage on one, peptides in the bottom half of four lists and dosed on none, caffeine on three lists and claimed against a fourth, a fragrance entry on one, are counts of the Card's printed record and are printed as counts so they can be recounted.

On the brief's premises, and the two precisions this issue carries. This issue was briefed on three counts, and all three survived the record: one maker claiming caffeine in its copy and its FAQ while caffeine stands nowhere on its published list; a headline active carrying a printed percentage on exactly one of the eight records, the bottle that puts the dose in its name; and peptides sitting in the bottom half of all four lists that carry them, dosed on none. Two precisions are printed rather than absorbed. First, the brief understated the claim's venues: the caffeine is claimed not in two places but in three, the maker's copy, its FAQ and its key-ingredient panel, and the third is the strongest of them, because a key-ingredient panel is an inventory by genre, the one part of a product page whose whole job is to enumerate contents, so the claim fails not as advertising but as documentation. Second, the word refuted carries the Card's own limit, and this Take adopts it as a limit on its headline: the refutation holds of the published list, read entire on the maker's own product page, the only list a buyer can check before paying. Whether the physical jar's printed list matches the published one is exactly what the document cannot show; the Card prints the invitation, that a maker whose jar differs should publish the jar's list where a reader can find it, and stands the card for re-reading in November. What is claimed here is the documentary fact, that the claim and the list cannot both be read as true of the same bottle, and not a chemical analysis of any jar.

On what eye creams do. Nothing on this page says any bottle depuffs, brightens or repairs any eye, and nothing says any peptide works or fails at any position. Efficacy is graded nowhere here: where the published literature on a named complex is real, it is the suppliers', and it is credited to them in the counter-argument and the questions alike. What is graded is the document the buyer is handed: where the actives stand, what is dosed, and whether the claims printed around a list can be cashed by the list itself. The desk opened no bottle and wore no cream. A reader's own eyes are the final instrument on this shelf; the argument is about what is printed for him to read before he becomes the instrument, and on one page what is printed in three places is an ingredient the fourth document does not contain.

On the photographs, and on the record moving. There are no photographs of ranked products on this page because there are none to print: the photo bank holds no eye cream product photography, no bottle, dropper or bathroom-shelf frames, a gap the Card names on its own page, and the hero and figure here are frames of the subject itself, the ranking's own hero and a bank portrait in round tortoise frames from the face-shape Decoder's spokes, captioned for what they show, which is a face behind frames, not a product. The record itself moves underneath this argument: prices drift by door (the Jack Black's $40 standing on retail records with one aggregator reading $41 in October, and its exact capturable door owed to the November pass; the skip's American price standing on its Amazon listing, its maker pricing regionally), documents diverge (the winner's two renderings, with which one a given tube carries owed to November; the La Roche-Posay's list read on a European rendering against its American key-ingredient page), and one list is owed a re-read above all, the Brickell's, against the jar's printed list, for the reason this whole issue exists. The scores and the rule stand as published until a cited record changes; when one does, the Card moves first and this Take is re-argued from it, in the open.

Questions, answered from the record

Next

The record this issue argues from stands in full at the eye cream ranking, Verdict Card No. 90, where every list quoted here is printed in its maker's order and every bottle carries its own card. The shelf above the sink continues at the moisturizer Card, No. 66, the cleanser Card, No. 67, the sunscreen Card, No. 68, and the aftershave Card, No. 89, and the routine that orders them stands at the skincare Decoder. The kinship runs three ways: Take No. 6 is the parent argument, of which this shelf is the second case, since there the founding bottle and the skip carried no salt of any kind under names that sold it, and here an active stands claimed in a maker's copy, FAQ and ingredient panel over a list that employs it nowhere; Take No. 2 governs the dose half, the number nobody prints, which on this shelf is printed once, in a name, while the numbers that circulate, 28 and 45, belong to suppliers and measure other formulas; and Take No. 12 supplies the nearest precedent, the burn is not the proof, since on the aftershave shelf a balm's copy claimed an aloe and an allantoin no captured list carries, charged in a line on its card, and here the same pattern is the headline, claimed in three documentary venues on one page. The franchise so far: No. 1, grooming is sold by the step and works by the habit; No. 2, the number nobody prints; No. 3, one tube, two honesties; No. 4, the pair graded as one record; No. 5, the name is not the number; No. 6, the name is not in the list; No. 7, the number is not the dose; No. 8, the minute is the dose; No. 9, the ritual is not an ingredient; No. 10, the hold is an adjective; No. 11, the name is not an ingredient; No. 12, the burn is not the proof. How every score on this site is built is set out in the methodology. The Takes continue by number; the next one starts, as this one did, from a record that already exists or a blank that is printed as one.